In TNBC, the presence of tumor-infiltrating lymphocytes (TILs) in residual disease after neoadjuvant chemotherapy is associated with improved prognosis, and genomic or transcriptomic activation of the RAS/RAF/MEK/ERK pathway correlates with lower TILs. This evidence concerns the gene MAP2K7 and neoplasm.